Advisory Board May 22, 2024

Weight-loss drugs like Wegovy and Zepbound are in high demand, but their expensive price tags have made them unaffordable for many patients. However, some telehealth companies are now offering their own versions of these weight-loss drugs at a significant discount — something that could significantly increase access to these medications.

Resource library: Weight management and obesity care

High costs of GLP-1 drugs push out low-income patients

GLP-1 agonists, which include Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro, were originally approved to treat diabetes. Over the last few years, FDA has also approved rebranded versions of these drugs, including Novo’s Wegovy and Lilly’s Zepbound, to treat obesity.

Although these drugs are in high demand, their high costs have made it difficult...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Digital Health, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Technology, Telehealth, Trends
Telehealth arrests at a key time for the industry
5 Trends to Combat Staff Shortages & Boost Healthcare Efficiency
Talkiatry Raises $130M, Vows Pivot to Value-Based Care
Telepsychiatry Practice Talkiatry Secures $130M to Expand Value-Based Mental Healthcare Model
Telehealth firm fraud charges may worsen ADHD drug shortage

Share This Article